{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:22:31Z","timestamp":1790781751782,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T00:00:00Z","timestamp":1479081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T00:00:00Z","timestamp":1479081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,2,23]]},"DOI":"10.1038\/onc.2016.272","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T16:39:24Z","timestamp":1479141564000},"page":"1080-1089","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma"],"prefix":"10.1038","volume":"36","author":[{"given":"J M","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q H","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M W","family":"Pavesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Nesterenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L J","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A C","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O V","family":"Razorenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,14]]},"reference":[{"key":"BFonc2016272_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A . Cancer statistics 2016. Cancer J Clin 2016; 66: 7\u201330.","journal-title":"Cancer J Clin"},{"key":"BFonc2016272_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S0022-5347(05)67889-5","volume":"163","author":"RJ Motzer","year":"2000","unstructured":"Motzer RJ, Russo P . Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408\u2013417.","journal-title":"J Urol"},{"key":"BFonc2016272_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics 2014. Cancer J Clin 2014; 64: 9\u201329.","journal-title":"Cancer J Clin"},{"key":"BFonc2016272_CR4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.14712\/fb2008054060187","volume":"192","author":"I Hodorova","year":"2008","unstructured":"Hodorova I, Rybarova S . Multidrug resistance proteins in renal cell carcinoma. Folia Biol 2008; 192: 187\u2013192.","journal-title":"Folia Biol"},{"key":"BFonc2016272_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1541-7786.MCR-12-0117","volume":"10","author":"E Jonasch","year":"2012","unstructured":"Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J et al. State of the science: an update on renal cell carcinoma. Mol Cancer Res 2012; 10: 859\u2013880.","journal-title":"Mol Cancer Res"},{"key":"BFonc2016272_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11912-009-0015-5","volume":"11","author":"CL Cowey","year":"2009","unstructured":"Cowey CL, Rathmell WK . VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009; 11: 94\u2013101.","journal-title":"Curr Oncol Rep"},{"key":"BFonc2016272_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2012.00035","volume":"2","author":"Q Zhang","year":"2012","unstructured":"Zhang Q, Yang H . The roles of VHL-dependent ubiquitination in signaling and cancer. Front Oncol 2012; 2: 1\u20137.","journal-title":"Front Oncol"},{"key":"BFonc2016272_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl JMed 2007; 356: 115\u2013124.","journal-title":"N Engl JMed"},{"key":"BFonc2016272_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"456","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl JMed 2007; 456: 125\u2013134.","journal-title":"N Engl JMed"},{"key":"BFonc2016272_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/11591240-000000000-00000","volume":"11","author":"B Escudier","year":"2011","unstructured":"Escudier B, Gore M . Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 2011; 11: 113\u2013126.","journal-title":"Drugs R D"},{"key":"BFonc2016272_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061\u20131068.","journal-title":"J Clin Oncol"},{"key":"BFonc2016272_CR12","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584\u20133590.","journal-title":"J Clin Oncol"},{"key":"BFonc2016272_CR13","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010; 116: 4256\u20134265.","journal-title":"Cancer"},{"key":"BFonc2016272_CR14","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"M Hudes Carducci","year":"2007","unstructured":"Hudes Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al. The global ARCC G. Temsirolimus, interferon alpha or both for advanced renal cell carcinoma. N Engl J Med 2007; 356: 2271\u20132281.","journal-title":"N Engl J Med"},{"key":"BFonc2016272_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.clgc.2014.06.012","volume":"12","author":"A Pinto","year":"2014","unstructured":"Pinto A . Adjuvant therapy for renal cell carcinoma. Clin Genitourin Cancer 2014; 12: 408\u2013412.","journal-title":"Clin Genitourin Cancer"},{"key":"BFonc2016272_CR16","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","volume":"10","author":"BI Rini","year":"2009","unstructured":"Rini BI, Atkins MB . Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992\u20131000.","journal-title":"Lancet Oncol"},{"key":"BFonc2016272_CR17","first-page":"31","volume":"1845","author":"M Buczek","year":"2014","unstructured":"Buczek M, Escudier B, Bartnik E, Szczylik C, Czarnecka A . Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient\u2019s bed to molecular mechanisms. Biochim Biophys Acta 2014; 1845: 31\u201341.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2016272_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrd3374","volume":"10","author":"D Chan","year":"2011","unstructured":"Chan D, Giaccia AJ . Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011; 10: 351\u2013364.","journal-title":"Nat Rev Drug Discov"},{"key":"BFonc2016272_CR19","first-page":"1","volume":"88","author":"JM Thompson","year":"2015","unstructured":"Thompson JM, Nguyen QH, Singh M, Razorenova O . Approaches to identifying synthetic lethal interactions in cancer. Yale J Biol Med 2015; 88: 1\u201311.","journal-title":"Yale J Biol Med"},{"key":"BFonc2016272_CR20","first-page":"94ra70","volume":"3","author":"Da Chan","year":"2011","unstructured":"Chan Da, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 2011; 3: 94ra70.","journal-title":"Sci Transl Med"},{"key":"BFonc2016272_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ccr.2008.06.004","volume":"14","author":"S Turcotte","year":"2008","unstructured":"Turcotte S, Chan D, Sutphin PD, Hay MP, Denny WA, Giaccia AJ . A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 2008; 14: 90\u2013102.","journal-title":"Cancer Cell"},{"key":"BFonc2016272_CR22","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1158\/0008-5472.CAN-07-0604","volume":"67","author":"PD Sutphin","year":"2007","unstructured":"Sutphin PD, Chan D, Li JM, Turcotte S, Krieg AJ, Giaccia AJ . Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Cancer Res 2007; 67: 5896\u20135905.","journal-title":"Cancer Res"},{"key":"BFonc2016272_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1593\/neo.12852","volume":"14","author":"GM Woldemichael","year":"2012","unstructured":"Woldemichael GM, Turbyville TJ, Vasselli JR, Linehan WM, McMahon JB . Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A. Neoplasia 2012; 14: 771\u2013777.","journal-title":"Neoplasia"},{"key":"BFonc2016272_CR24","doi-asserted-by":"publisher","first-page":"16951","DOI":"10.18632\/oncotarget.4773","volume":"6","author":"NC Wolff","year":"2015","unstructured":"Wolff NC, Pav\u00eda-Jim\u00e9nez A, Tcheuyap VT, Alexander S, Vishwanath M, Christie A et al. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma. Oncotarget 2015; 6: 16951\u201316962.","journal-title":"Oncotarget"},{"key":"BFonc2016272_CR25","doi-asserted-by":"publisher","first-page":"16484","DOI":"10.1073\/pnas.0806574105","volume":"105","author":"A Bommi-Reddy","year":"2008","unstructured":"Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL-\/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 2008; 105: 16484\u201316489.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2016272_CR26","doi-asserted-by":"publisher","first-page":"e483","DOI":"10.1038\/cddis.2013.10","volume":"4","author":"J Shi","year":"2013","unstructured":"Shi J, Wu X, Surma M, Vemula S, Zhang L, Yang Y et al. Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment. Cell Death Dis 2013; 4: e483.","journal-title":"Cell Death Dis"},{"key":"BFonc2016272_CR27","first-page":"2632","volume":"9","author":"T Kamai","year":"2003","unstructured":"Kamai T, Tsujii T, Arai K . Significant association of Rho \/ ROCK pathway with invasion and metastasis of bladder cancer significant association of Rho \/ ROCK pathway with invasion and metastasis of bladder cancer 1. Clin Cancer Res 2003; 9: 2632\u20132641.","journal-title":"Clin Cancer Res"},{"key":"BFonc2016272_CR28","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-0436-03","volume":"10","author":"T Kamai","year":"2004","unstructured":"Kamai T, Yamanishi T, Shirataki H, Takagi K, Asami H, Ito Y et al. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res 2004; 10: 4799\u20134805.","journal-title":"Clin Cancer Res"},{"key":"BFonc2016272_CR29","first-page":"585","volume":"33","author":"J Lane","year":"2008","unstructured":"Lane J, Martin T, Watkins G, Mansel R, Jiang W . The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 2008; 33: 585\u2013593.","journal-title":"Int J Oncol"},{"key":"BFonc2016272_CR30","doi-asserted-by":"publisher","first-page":"5582","DOI":"10.1038\/onc.2013.505","volume":"33","author":"C Zhang","year":"2014","unstructured":"Zhang C, Zhang S, Zhang Z, He J, Xu Y, Liu S . ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc. Oncogene 2014; 33: 5582\u20135591.","journal-title":"Oncogene"},{"key":"BFonc2016272_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2220\/biomedres.29.155","volume":"29","author":"H Abe","year":"2008","unstructured":"Abe H, Kamai T, Tsujii T, Nakamura F, Mashidori T, Mizuno T et al. Possible role of the RhoC\/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res 2008; 29: 155\u2013161.","journal-title":"Biomed Res"},{"key":"BFonc2016272_CR32","doi-asserted-by":"publisher","first-page":"8742","DOI":"10.1158\/0008-5472.CAN-09-1541","volume":"69","author":"S Liu","year":"2009","unstructured":"Liu S, Goldstein RH, Scepansky EM, Rosenblatt M . Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009; 69: 8742\u20138751.","journal-title":"Cancer Res"},{"key":"BFonc2016272_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/FJC.0b013e318070d1bd","volume":"50","author":"JK Liao","year":"2007","unstructured":"Liao JK, Seto M, Noma K . Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007; 50: 17\u201324.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFonc2016272_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellsig.2012.09.010","volume":"25","author":"A Mleczak","year":"2013","unstructured":"Mleczak A, Millar S, Tooze SA, Olson MF, Chan EYW . Regulation of autophagosome formation by Rho kinase. Cell Signal 2013; 25: 1\u201311.","journal-title":"Cell Signal"},{"key":"BFonc2016272_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0014-5793(96)00811-3","volume":"392","author":"O Nakagawa","year":"1996","unstructured":"Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S . ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine\/threonine kinase in mice. FEBS Lett 1996; 392: 189\u2013193.","journal-title":"FEBS Lett"},{"key":"BFonc2016272_CR36","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1128\/MCB.00644-12","volume":"34","author":"O Razorenova","year":"2014","unstructured":"Razorenova O, Castellini L, Colavitti R, Edgington LE, Nicolau M, Huang X et al. The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells. Mol Cell Biol 2014; 34: 739\u2013751.","journal-title":"Mol Cell Biol"},{"key":"BFonc2016272_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271\u2013275.","journal-title":"Nature"},{"key":"BFonc2016272_CR38","doi-asserted-by":"publisher","first-page":"40112","DOI":"10.1074\/jbc.M206922200","volume":"277","author":"D Chan","year":"2002","unstructured":"Chan D, Sutphin PD, Denko NC, Giaccia AJ . Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem 2002; 277: 40112\u201340117.","journal-title":"J Biol Chem"},{"key":"BFonc2016272_CR39","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1515\/hsz-2013-0181","volume":"394","author":"E Amin","year":"2013","unstructured":"Amin E, Dubey BN, Zhang SC, Gremer L, Dvorsky R, Moll JM et al. Rho-kinase: regulation, (dys)function, and inhibition. Biol Chem 2013; 394: 1399\u20131410.","journal-title":"Biol Chem"},{"key":"BFonc2016272_CR40","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1158\/0008-5472.CAN-12-0954","volume":"72","author":"R Patel","year":"2012","unstructured":"Patel R, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP et al. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res 2012; 72: 5025\u20135034.","journal-title":"Cancer Res"},{"key":"BFonc2016272_CR41","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharep.2013.06.006","volume":"66","author":"D Isler","year":"2014","unstructured":"Isler D, Ozaslan M, Karagoz ID, Kilic IH, Karakok M, Taysi S et al. Antitumoral effect of a selective Rho-kinase inhibitor Y-27632 against Ehrlich ascites carcinoma in mice. Pharmacol Rep 2014; 66: 114\u2013120.","journal-title":"Pharmacol Rep"},{"key":"BFonc2016272_CR42","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1161\/01.STR.0000181077.84981.11","volume":"36","author":"Y Rikitake","year":"2005","unstructured":"Rikitake Y, Kim H-H, Huang Z, Seto M, Yano K, Asano T et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005; 36: 2251\u20132257.","journal-title":"Stroke"},{"key":"BFonc2016272_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/bjp.2008.225","volume":"155","author":"S Inan","year":"2008","unstructured":"Inan S, B\u00fcy\u00fckaf\u015far K . Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br J Pharmacol 2008; 155: 44\u201351.","journal-title":"Br J Pharmacol"},{"key":"BFonc2016272_CR44","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1046\/j.1523-1755.2002.00328.x","volume":"61","author":"K Nagatoya","year":"2002","unstructured":"Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61: 1684\u20131695.","journal-title":"Kidney Int"},{"key":"BFonc2016272_CR45","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","volume":"14","author":"J Gordan","year":"2008","unstructured":"Gordan J, Lal P, Dondeti V, Letrero R . HIF-\u03b1 effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14: 435\u2013446.","journal-title":"Cancer Cell"},{"key":"BFonc2016272_CR46","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1038\/onc.2010.3","volume":"29","author":"P Lochhead","year":"2010","unstructured":"Lochhead P, Wickman G, Mezna M, Olson MF . Activating ROCK1 somatic mutations in human cancer. Oncogene 2010; 29: 2591\u20132598.","journal-title":"Oncogene"},{"key":"BFonc2016272_CR47","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jor.21403","volume":"29","author":"X Liu","year":"2011","unstructured":"Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D et al. ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res 2011; 29: 1259\u20131266.","journal-title":"J Orthop Res"},{"key":"BFonc2016272_CR48","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrc1187","volume":"3","author":"GL Semenza","year":"2003","unstructured":"Semenza GL . Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721\u2013732.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2016272_CR49","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/sj.cdd.4402313","volume":"15","author":"PP Kapitsinou","year":"2008","unstructured":"Kapitsinou PP, Haase VH . The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ 2008; 15: 650\u2013659.","journal-title":"Cell Death Differ"},{"key":"BFonc2016272_CR50","doi-asserted-by":"publisher","first-page":"E384","DOI":"10.1073\/pnas.1321510111","volume":"111","author":"DM Gilkes","year":"2013","unstructured":"Gilkes DM, Xiang L, Lee SJ, Chaturvedi P, Hubbi ME, Wirtz D et al. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci USA 2013; 111: E384\u2013E393.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2016272_CR51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/path.1778","volume":"206","author":"AE Greijer","year":"2005","unstructured":"Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA et al. Up-regualtion of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor I (HIF-I). J Pathol 2005; 206: 291\u2013304.","journal-title":"J Pathol"},{"key":"BFonc2016272_CR52","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1242\/jcs.00427","volume":"116","author":"S Turcotte","year":"2003","unstructured":"Turcotte S . HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci 2003; 116: 2247\u20132260.","journal-title":"J Cell Sci"},{"key":"BFonc2016272_CR53","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1158\/1535-7163.MCT-07-0428","volume":"7","author":"K Takata","year":"2008","unstructured":"Takata K, Morishige K-I, Takahashi T, Hashimoto K, Tsutsumi S, Yin L et al. Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells. Mol Cancer Ther 2008; 7: 1551\u20131561.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2016272_CR54","doi-asserted-by":"publisher","first-page":"13957","DOI":"10.1074\/jbc.M511763200","volume":"281","author":"Y Mizukami","year":"2006","unstructured":"Mizukami Y, Fujiki K, Duerr E-M, Gala M, Jo W-S, Zhang X et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase\/Rho\/ROCK and c-Myc. J Biol Chem 2006; 281: 13957\u201313963.","journal-title":"J Biol Chem"},{"key":"BFonc2016272_CR55","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1073\/pnas.1011777108","volume":"108","author":"O Razorenova","year":"2011","unstructured":"Razorenova O, Finger E, Colavitti R, Chernikova S, Boiko A, Chan C et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci USA 2011; 108: 1931\u20131936.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2016272_CR56","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.gene.2005.02.006","volume":"350","author":"O Razorenova","year":"2005","unstructured":"Razorenova O, Ivanov V, Budanov V, Chumakov P . Virus-based reporter systems for monitoring transcriptional activity of hypoxia-inducible factor 1. Gene 2005; 350: 89\u201398.","journal-title":"Gene"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2016272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2016272","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2016272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T14:08:32Z","timestamp":1749737312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2016272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,14]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,2,23]]}},"alternative-id":["BFonc2016272"],"URL":"https:\/\/doi.org\/10.1038\/onc.2016.272","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,14]]},"assertion":[{"value":"5 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}